

Drug	Schedule	Drug	Schedule
N-Hydroxy-3,4-methylenedioxyamphetamine (7402).	I	Phenmetrazine (1631)	II
3,4-Methylenedioxy-N-ethylamphetamine (7404).	I	Methylphenidate (1724)	II
3,4-Methylenedioxy-N-methylamphetamine (7405).	I	Amobarbital (2125)	II
4-Methoxyamphetamine (7411) ...	I	Pentobarbital (2270)	II
5-Methoxy-N,N-dimethyltryptamine (7431).	I	Secobarbital (2315)	II
Alpha-methyltryptamine (7432)	I	Glutethimide (2550)	II
Bufotenine (7433)	I	Nabilone (7379)	II
Diethyltryptamine (7434)	I	1-Phenylcyclohexylamine (7460)	II
Dimethyltryptamine (7435)	I	Phencyclidine (7471)	II
Psilocybin (7437)	I	1-Piperidinocyclohexanecarbonitrile (8603).	II
Psilocyn (7438)	I	Alphaprodine (9010)	II
5-Methoxy-N,N-diisopropyltryptamine (7439).	I	Cocaine (9041)	II
N-Ethyl-1-phenylcyclohexylamine (7455).	I	Codeine (9050)	II
1-(1-Phenylcyclohexyl)pyrrolidine (7458).	I	Dihydrocodeine (9120)	II
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470).	I	Oxycodone (9143)	II
N-Benzylpiperazine (7493)	I	Hydromorphone (9150)	II
Acetyldihydrocodeine (9051)	I	Diphenoxylate (9170)	II
Benzylmorphine (9052)	I	Benzoylcegonine (9180)	II
Codeine-N-oxide (9053)	I	Ethylmorphine (9190)	II
Codeine methylbromide (9070)	I	Hydrocodone (9193)	II
Dihydromorphone (9145)	I	Levomethorphan (9210)	II
Heroin (9200)	I	Levorphanol (9220)	II
Hydromorphinol (9301)	I	Isomethadone (9226)	II
Methyldesorphine (9302)	I	Meperidine (9230)	II
Methyldihydromorphone (9304)	I	Meperidine Intermediate-A (9232)	II
Morphine methylbromide (9305) ..	I	Meperidine Intermediate-B (9233)	II
Morphine methylsulfonate (9306)	I	Meperidine Intermediate-C (9234)	II
Morphine-N-oxide (9307)	I	Metazocine (9240)	II
Normorphine (9313)	I	Methadone (9250)	II
Pholcodine (9314)	I	Methadone Intermediate (9254) ...	II
Acetylmethadol (9601)	I	Dextropropoxyphene, bulk (non-dosage forms) (9273).	II
Allylprodine (9602)	I	Morphine (9300)	II
Alphacetylmethadol except levo-alphacetylmethadol (9603).	I	Thebaine (9333)	II
Alphameprodine (9604)	I	Levo-alphacetylmethadol (9648) ..	II
Alphamethadol (9605)	I	Oxymorphone (9652)	II
Betacetylmethadol (9607)	I	Noroxymorphone (9668)	II
Betameprodine (9608)	I	Racemethorphan (9732)	II
Betamethadol (9609)	I	Alfentanil (9737)	II
Betaprodine (9611)	I	Remifentanil (9739)	II
Dipipanone (9622)	I	Sufentanil (9740)	II
Hydroxypethidine (9627)	I	Carfentanil (9743)	II
Noracymethadol (9633)	I	Tapentadol (9780)	II
Norlevorphanol (9634)	I	Fentanyl (9801)	II
Normethadone (9635)	I		
Trimeperidine (9646)	I		
Phenomorphan (9647)	I		
1-Methyl-4-phenyl-4-propionoxypiperidine (9661).	I		
Tilidine (9750)	I		
Para-Fluorofentanyl (9812)	I		
3-Methylfentanyl (9813)	I		
Alpha-Methylfentanyl (9814)	I		
Acetyl-alpha-methylfentanyl (9815).	I		
Beta-hydroxyfentanyl (9830)	I		
Beta-hydroxy-3-methylfentanyl (9831).	I		
Alpha-methylthiofentanyl (9832) ...	I		
3-Methylthiofentanyl (9833)	I		
Thiofentanyl (9835)	I		
Amphetamine (1100)	II		
Methamphetamine (1105)	II		
Lisdexamfetamine (1205)	II		

Dated: August 17, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-21276 Filed 8-28-12; 8:45 am]

BILLING CODE 4410-09-P**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****Manufacturer of Controlled Substances; Notice of Application; Euticals Inc.**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 7, 2012, Euticals Inc., (formerly known as Archimica, Inc.) 2460 W. Bennett Street, Springfield, Missouri 65807-1229, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Gamma Hydroxybutyric Acid (2010).	I
Amphetamine (1100)	II
Lisdexamfetamine (1205)	II
Methylphenidate (1724)	II
Phenylacetone (8501)	II
Methadone Intermediate (9254) ...	II
Tapentadol (9780)	II

The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers.

With regards to Amphetamine (1100), the company plans to acquire the listed controlled substance in bulk from a domestic source in order to manufacture other controlled substances in bulk for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 29, 2012.

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than October 29, 2012.

Dated: August 17, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-21280 Filed 8-28-12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration; Austin Pharma, LLC.

By Notice dated May 9, 2012, and published in the **Federal Register** on May 21, 2012, 77 FR 30027, Austin Pharma LLC., 811 Paloma Drive, Suite C, Round Rock, Texas 78665-2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I

The company plans to manufacture bulk active pharmaceutical ingredients (APIs) for distribution to its customers.

In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Austin Pharma LLC., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Austin Pharma LLC., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR § 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: August 17, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-21283 Filed 8-28-12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration; Agilent Technologies

By Notice dated May 11, 2012, and published in the **Federal Register** on May 21, 2012, 77 FR 30025, Agilent Technologies, 25200 Commercentre Drive, Lake Forest, California 92630-8810, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Phencyclidine (7471)	II
1-piperidinocyclohexanecarbonitrile (8603)	II
Benzoyllecgonine (9180)	II

The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Agilent Technologies to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Agilent Technologies to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR § 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: August 17, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-21282 Filed 8-28-12; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration; American Radiolabeled Chemicals, Inc.

By Notice dated May 9, 2012, and published in the **Federal Register** on May 21, 2012, 77 FR 30027, American Radiolabeled Chemicals, INC., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Gamma Hydroxybutyric Acid (2010)	I
Ibogaine (7260)	I
Lysergic acid diethylamide (7315)	I
Tetrahydrocannabinols (7370)	I
Dimethyltryptamine (7435)	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470)	I
Dihydromorphine (9145)	I
Normorphine (9313)	I
Heroin (9200)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Amobarbital (2125)	II
Phencyclidine (7471)	II
Phenylacetone (8501)	II
Cocaine (9041)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Ecgonine (9180)	II
Hydrocodone (9193)	II
Meperidine (9230)	II
Metazocine (9240)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Morphine (9300)	II
Oripavine (9330)	II
Thebaine (9333)	II
Oxymorphone (9652)	II
Phenazocine (9715)	II
Carfentanil (9743)	II
Fentanyl (9801)	II

The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of American Radiolabeled Chemicals, INC., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated American Radiolabeled Chemicals INC., to ensure that the company's registration is consistent with the public